Concentration in tebipenem HBr and GSK collaboration
The business is substantially dependent on one late-stage program and one major partner.
- Scope
- Pipeline concentration
- Materiality
- high
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multidrug-resistant bacterial infections. Its pipeline has included tebipenem HBr, SPR720, and SPR206, with development activities supported through collaborations and government funding arrangements.
9,5 %
12,8 %
+39,2 %
7.59
7.59
| % | |
|---|---|
| Tebipenem HBr | 95% Oral broad-spectrum carbapenem candidate for complicated urinary tract infections and pyelonephritis. |
| Collaboration revenue | 5% Revenue recognized under license and development agreements with partners such as GSK and Pfizer. |
| SPR720 | 0% Oral investigational therapy for nontuberculous mycobacterial pulmonary disease. |
| SPR206 | 0% Investigational anti-infective program for multidrug-resistant bacterial infections. |
Spero’s direct commercial customers are not yet established because it is still a clinical-stage company...
- Pharmaceutical collaboration partnersprimary
Partners such as GSK and Pfizer support development programs and share in the economics of selected assets.
- Government funding agenciesprimary
Agencies such as NIAID support preclinical and clinical development through awards and contracts.
- Hospitals and inpatient providerssecondary
Potential future buyers for tebipenem HBr if approved for inpatient or bundled-payment settings.
- Government and commercial payorssecondary
They determine coverage and reimbursement levels that affect future adoption and pricing.
- Infectious disease physicianssecondary
Prescribers who would use the company’s anti-infective products for resistant infections.
Spero is headquartered in the United States and conducts development activities through a U.S...
- •Headquartered in the United States
- •Clinical development and corporate functions are U.S.-based
- •Third-party contract manufacturers are based in Asia
- •Some manufacturing facilities are in Taiwan
- •Future commercialization would depend on U.S. and international reimbursement
Spero’s strategy is centered on advancing tebipenem HBr through late-stage development and regulatory filing while...
01
Advance tebipenem HBr to approval pathwayshort-term
This asset is the main value driver and the most advanced program in the pipeline.
02
Maintain external funding sourcesshort-term
The company depends on non-product revenue until commercialization is possible.
03
Preserve pipeline optionalitymedium-term
Earlier-stage programs may still create value if a viable path forward is found.
Spero is highly dependent on the success of a small number of development assets, especially tebipenem HBr and its GSK...
Clinical development failure
Drug candidates may not meet endpoints, show safety issues, or fail to gain approval.
- Scope
- Phase 3 and regulatory pathway
- Materiality
- high
Manufacturing and supply chain disruption
The company relies on a small number of third-party manufacturers and one raw-material supplier.
- Scope
- Asia/Taiwan supply chain
- Materiality
- high
Financing risk
The company expects to need external funding until product sales are established.
- Scope
- Equity, debt, collaborations, grants
- Materiality
- high
Reimbursement and pricing pressure
Hospital bundled payments and payor controls can limit uptake and pricing power.
- Scope
- U.S. and international commercialization
- Materiality
- high
Collaboration revenue recognition
GSK and Pfizer agreements
Grant revenue and government awards
NIAID and other awards
Lease accounting and impairment
Reported operating expense and asset values
Stock-based compensation
Operating loss and dilution analysis
Foreign currency remeasurement
Other income (expense), net
VERU INC.
VERU · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
Esperion Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on oral, once-daily, non-statin medicines for lowering LDL-C and reducing cardiovascular risk.
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
: 29.4.2026